News
Affluent Medical announces 15.8m€ in new financing and strengthening of its board of Directors
The Private Placement Financing was taken out for gross proceeds of €10.3 million, €8 million via convertible bonds (of which €4 million were received in December 2019). Affluent Medical has been granted two “PGE” (government-backed) loans for a...
Affluent Medical announces the launch of MINERVA First-In-Human clinical study for EPYGON
Epygon is the first transcatheter mitral valve designed to restore the physiological blood flow vortex and treat left ventricle disease, in particular in so-called “functional” patients. No mitral valve prosthesis currently on the market or in...
Affluent Medical announces first patient implanted in OPTIMISE II pivotal clinical study for KALIOS, the minimally invasive mitral valve repair ring
KALIOS is the first fully adjustable mitral valve repair ring, designated for the percutaneous treatment of both residual and recurrent Mitral Regurgitation (MR). First patient implanted in Vienna General Hospital (AKH) Obtention of regulatory...
Affluent Medical strengthens its executive team
Michel Finance is appointed CEO.Executive team is strengthened with the appointment of:Daniele Zanotti (the former CEO) as Chief Technology and Innovation Officer leading technology developments and the execution of programs,Professor François...
Affluent Medical releases impressive results from SCOPE 1 clinical trial validating efficacy of KARDIOZIS technology
Outstanding results from SCOPE 1 randomized, controlled, multicentric clinical trial, proving the efficacy of treating life-threatening Abdominal Aortic Aneurysm (AAA), by thrombogenic fibers embolization of the aneurysm sac when performing an...
Affluent medical secures up to eur 12m debt financing from kreos capital
EUR 12 million financing comprising three tranches of EUR 4 million straight bonds. Clearing financial path to achieve major clinical milestones in view of regulatory approvals.
